Track topics on Twitter Track topics that are important to you
No Summary Available
This article was published in the following journal.
Name: Hematological oncology
Impact of intended and relative dose intensity of R-CHOP in a large, consecutive cohort of elderly Diffuse large B cell lymphoma (DLBCL) patients treated with curative intent: no difference in cumulative incidence of relapse comparing patients by age.
The increasing incidence of DLBCL in aging populations places a significant burden on healthcare systems. Co-morbidity, frailty, and reduced organ and physiological reserve contribute to treatment-rel...
Spatial Dose Patterns Associated with Radiation Pneumonitis in a Randomized Trial Comparing Intensity-Modulated Radiation Therapy with Passive Scattering Proton Therapy for Locally Advanced Non-Small Cell Lung Cancer.
Radiation pneumonitis (RP) is commonly associated with thoracic radiation therapy (RT), and its incidence is related to dose and volume of the normal lung in the path of radiation. Our aim was to inve...
The efficacy of accelerator-based boron neutron capture therapy was examined through relative-biological-effectiveness dose calculations with the fast-neutron dose per epithermal neutron (FNR) and the...
A novel method to address the association between received dose intensity and survival outcome: benefits of approaching treatment intensification at a more individualised level in a trial of the European Osteosarcoma Intergroup.
There is lack of consensus on the prognostic value of received high dose intensity in osteosarcoma survivorship. Many studies have not shown a clear survival benefit when dose intensity is increased. ...
Helicobacter pylori treatment recommendations often recommend use of double-dose PPI or greater. This is confusing because PPIs very markedly in relative potency such that a double dose of one may not...
The purpose of this trial is to investigate the clinical benefit of the dose intensified regimen, Bi-CHOP in comparison to standard CHOP for advanced intermediate or high grade non-Hodgkin...
This is a multicenter, open-label, dose-finding study of GDC-0199 administered orally in combination with MabThera/Rituxan (R) or obinutuzumab (G) and standard doses of cyclophosphamide, d...
This is an observational study aimed to analyze the effectiveness of treatment of patients with newly dg. mantle cell lymphoma not eligible for high-dose therapy and autologous stem cell t...
The study hypothesis is that intensification of CHOP by dose escalation of the most active drugs in the combination will improve treatment outcome. Patients with diffuse large-cell lymphom...
The goal of this clinical research study is to learn the effect of combining aprepitant with CHOP or R-CHOP in patients with NHL that is either newly diagnosed or has come back. Researcher...
CONFORMAL RADIOTHERAPY that combines several intensity-modulated beams to provide improved dose homogeneity and highly conformal dose distributions.
Evaluation procedures that focus on both the outcome or status (OUTCOMES ASSESSMENT) of the patient at the end of an episode of care - presence of symptoms, level of activity, and mortality; and the process (ASSESSMENT, PROCESS) - what is done for the patient diagnostically and therapeutically.
The use of multiple drugs administered to the same patient, most commonly seen in elderly patients. It includes also the administration of excessive medication. Since in the United States most drugs are dispensed as single-agent formulations, polypharmacy, though using many drugs administered to the same patient, must be differentiated from DRUG COMBINATIONS, single preparations containing two or more drugs as a fixed dose, and from DRUG THERAPY, COMBINATION, two or more drugs administered separately for a combined effect. (From Segen, Dictionary of Modern Medicine, 1992)
The dose amount of poisonous or toxic substance or dose of ionizing radiation required to kill 50% of the tested population.
A performance measure for rating the ability of a person to perform usual activities, evaluating a patient's progress after a therapeutic procedure, and determining a patient's suitability for therapy. It is used most commonly in the prognosis of cancer therapy, usually after chemotherapy and customarily administered before and after therapy. It was named for Dr. David A. Karnofsky, an American specialist in cancer chemotherapy.